DBV Technologies S.A.

DBV Technologies announced its inclusion in the Euronext Tech Leaders index, effective June 22, 2026. This index highlights high-growth European companies across technology and related sectors, recognizing their innovation and growth trajectory. CEO Daniel Tassé stated that this recognition reflects the strength of their science and progress in developing the VIASKIN® Peanut Patch for peanut allergy.

DBV Technologies announced a revision to its participation in the Goldman Sachs 47th Annual Global Healthcare Conference. CEO Daniel Tassé will not be available for the previously scheduled fireside chat due to an unavoidable travel disruption. However, other company management will still participate in 1-on-1 investor meetings at the conference on June 9, 2026, in Miami, FL.

DBV Technologies announced new positive data from its Phase 3 VITESSE study, demonstrating statistically significant efficacy of the VIASKIN Peanut Patch in children aged 4-7 years with peanut allergy and concomitant atopic conditions like asthma, other food allergies, or atopic dermatitis. The company also previewed the design of its recently initiated Phase 2 THRIVE study, which will evaluate the efficacy and safety of the VIASKIN Peanut Patch in achieving ad lib peanut consumption in infants aged 6-12 months. Both sets of findings will be presented at the EAACI Congress 2026.

DBV Technologies announced that its Chief Executive Officer, Daniel Tassé, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is scheduled for June 9, 2026, at 9:20 AM ET, and a live webcast will be available. The company is a late-stage biopharmaceutical firm developing treatments for food allergies using its VIASKIN® patch technology.

DBV Technologies' Board of Directors approved the 2026 Performance Share Unit Plan and granted 4,060,000 Performance Share Units (PSUs) to CEO Daniel Tassé. The vesting of these PSUs is contingent upon achieving two key performance conditions related to U.S. Food and Drug Administration (FDA) approvals for Viaskin Peanut (VP) biologics license applications. The plan aims to align long-term value with company performance and leadership continuity, with vested shares delivered in installments from July 2028 to January 2030.

DBV Technologies S.A. announced its total number of voting rights and shares as of May 31, 2026, in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The company reported 296,061,497 total shares outstanding. The total gross voting rights matched the share count, while the total net voting rights, excluding shares without voting rights, were 295,906,088.

DBV Technologies announced that its shareholders approved all proposed resolutions at the 2026 Combined General Meeting. The meeting was chaired by Michel de Rosen, Chairman of the Board of Directors. The company has posted the resolutions and voting results on its website for public access.

DBV Technologies S.A. held its Annual Combined Meeting of Shareholders on June 3, 2026, where shareholders approved all thirty-nine proposals. Key approvals included the company's annual and consolidated financial statements for the year ended December 31, 2025, the renewal of KPMG as statutory auditor, and the ratification and renewal of several directors. Additionally, the company's bylaws were amended to set an age limit of 70 for the Chief Executive Officer and to comply with new French law provisions.

DBV Technologies announced the screening of the first participant in its THRIVE Phase 2 clinical study. This study evaluates the efficacy and safety of the VIASKIN® Peanut Patch in infants aged 6 to 12 months with peanut allergy, aiming for ad lib consumption of dietary peanut. The company believes this early, non-invasive intervention could alter the trajectory of peanut allergy in this young population, building on positive results observed in toddlers and older children.

DBV Technologies announced it will hold its Combined General Meeting on June 3, 2026, at 10:00 a.m. CEST at its headquarters in Châtillon, France. The preliminary notice was published on April 29, 2026, with the meeting notice following on May 13, 2026. Shareholders can access preparatory documents on the company's website, and requests for email delivery are accepted until May 29, 2026. The meeting will also be webcast live, with a recorded version available online within seven business days.